Hanwha Offers Up to $1.2 Billion for Austal US Business 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
US Judge Dismisses Gautam Adani Criminal Charges 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
WALTHAM, Mass., Feb. 20, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its fourth quarter and full year 2017 financial results will be released on Tuesday, February 27, 2018 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: (877) 412-6083
International Dial-in Number: (702) 495-1202
Conference ID: 5496159
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 5496159
A telephone replay will be available from approximately 11:00 a.m. ET on February 27, 2018 through midnight on March 5, 2018.
The webcast with slides will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will be archived on the website for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638
